Guangdong Zhongsheng Raynovent Biotechnology Co., Ltd. has completed the phase 1 clinical trial of ZSP1273, a Category 1 Drug which is being developed to prevent and treat influenza A and human avian influenza in The First Hospital of Jilin University. Phase 2 clinical trial of the drug will be launched soon.

The China National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application of Category 1 Drug ZSP0678 for Nonalcoholic steatohepatitis (NASH) indication.

The China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application of Category 1 Drug ZSP0678 for Nonalcoholic steatohepatitis (NASH) indication.